Actinogen Medical Ltd
ASX:ACW

Watchlist Manager
Actinogen Medical Ltd Logo
Actinogen Medical Ltd
ASX:ACW
Watchlist
Price: 0.07 AUD 1.45% Market Closed
Market Cap: 222.8m AUD
No Transactions Found

We don't have any information about ACW's insider trading.

Global
Insiders Monitor

Actinogen Medical Ltd
Glance View

Market Cap
222.4m AUD
Industry
Biotechnology

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in developing treatment for cognitive impairment associated with neurological diseases of raised cortisol levels inside brain cells. The firm's lead drug candidate, Xanamem, has been designed to block the production of cortisol the stress hormone in the brain. Xanamem is a unique inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the central nervous system. The company is an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s Disease, linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in neuropsychiatric diseases. The firm focuses on developing Phase II clinical trial evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer’s disease.

ACW Intrinsic Value
0.002 AUD
Overvaluation 97%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top